touchbionics.com/">Touch Bionics. Both companies have made global headlines with their innovative advances. In November 2011, Nanofiber Solutions played a key role in the world's second successful synthetic trachea transplant. The Columbus firm designed and built the nanofiber tracheal scaffold in which a cancer patient's own stem cells were grown before the transplantation on November 17th in Stockholm. 30-year-old, Christopher Lyles, from Baltimore, Maryland is making a good recovery. "It is an honor to contribute to this life-saving procedure," Nanofiber Solutions CEO Ross Kayuha said. "Successfully implanting a synthetic trachea using a patient's own stem cells is a significant milestone for regenerative medicine."
Despite challenging domestic and international economic climates, Ohio's bioscience industry remained stable, with categorical growth fueled by strategic state investment, favorable industry trends, and a qualified and plentiful workforce.
The bioscience sector is relatively small compared to other sectors in Ohio, but it is continuously growing. Currently more than 1,345 bioscience firms operate at 1,800 locations in Ohio, up from 1,115 firms operating 1,290 locations in 2000. Bioscience companies with operations in Ohio range from innovative start-ups supported by biotech incubators to emerging stars — like Meridian Bioscience, Atricure, Diagnostic Hybrids and Ganeden Biotech — to some of the largest corporations in the world — like Cardinal Health, P&G, Boehringer-Ingelheim and Abbott. Bioscience employment in Ohio has grown 19.5% since 2000, in contrast to a decline of 8.6% in total employment in Ohio.
Also increasing are the number of specialized graduates. According to BioOhio, in 2010, Ohio institutions awarded 8,088 bioscience related degrees, up 395 from the previous year. Comparing 2010 to 20
Page: 1 2 3 4 Related biology technology :1
|SOURCE Ohio Business Development Coalition|
Copyright©2010 PR Newswire.
All rights reserved
. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting2
. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology3
. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference4
. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.5
. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million6
. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer7
. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors8
. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference9
. HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology10
. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 201111
. Neurocrine Biosciences Reports Third Quarter 2011 Results